<DOC>
<DOCNO>EP-0619805</DOCNO> 
<TEXT>
<INVENTION-TITLE>
5-(HETERO- OR CARBOCYCLYLAMINO)-INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1 AGONISTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31505	C07D40306	A61K3152	A61K3140	C07D47300	A61K3141	A61K3142	A61P2500	A61K31425	A61P4300	A61K31505	C07D41312	A61K3141	A61K3140	A61P304	C07D20914	C07D40300	A61P4300	C07D20900	A61K3144	A61K314427	C07D41300	A61P2506	A61P2500	A61P2526	C07D40114	A61K31403	A61P2524	A61P908	A61P2530	A61P300	C07D20916	C07D41714	C07D40104	A61K3144	C07D40312	A61K31519	A61K3142	C07D41700	C07D47302	C07D41712	C07D40100	A61P2504	A61K314427	A61K31404	C07D40304	C07D47334	A61K31425	A61P2518	A61P2520	C07D40112	A61P900	A61K31403	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	A61K	A61K	C07D	A61K	A61K	A61P	A61K	A61P	A61K	C07D	A61K	A61K	A61P	C07D	C07D	A61P	C07D	A61K	A61K	C07D	A61P	A61P	A61P	C07D	A61K	A61P	A61P	A61P	A61P	C07D	C07D	C07D	A61K	C07D	A61K	A61K	C07D	C07D	C07D	C07D	A61P	A61K	A61K	C07D	C07D	A61K	A61P	A61P	C07D	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D403	A61K31	A61K31	C07D473	A61K31	A61K31	A61P25	A61K31	A61P43	A61K31	C07D413	A61K31	A61K31	A61P3	C07D209	C07D403	A61P43	C07D209	A61K31	A61K31	C07D413	A61P25	A61P25	A61P25	C07D401	A61K31	A61P25	A61P9	A61P25	A61P3	C07D209	C07D417	C07D401	A61K31	C07D403	A61K31	A61K31	C07D417	C07D473	C07D417	C07D401	A61P25	A61K31	A61K31	C07D403	C07D473	A61K31	A61P25	A61P25	C07D401	A61P9	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I) wherein Z is (a) or (b); R1 is (c), (d), (e) or (f); X is O, NH or S; A, B, D, E, and F are each independently C, N, O, or S; R2, R3, R4, R5 and R6 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkyl-aryl, halogen, cyano, nitro, -NR7R8, -(CH2)mOR9, -SR9, -SO2R9, -SO2NR7R8, -NR7SO2R8, -NR7CO2R9, -NR7COR9, -CONR7R8, or -CO2R9; one of R2 and R3, R3 and R4, R4 and R5, or R5 and R6 may be taken together to form a five- to seven-membered alkyl ring, a six-membered aryl ring, a five- to seven-membered heteroalkyl ring having 1 heteroatom of N, O, or S, or a five- or six-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R7 and R8 are each independently hydrogen, C1 to C6 alkyl, -(CH2)qR10, C1 to C3 alkyl-aryl, aryl, or may be taken together to form a four- to six-membered ring; R9 is hydrogen, C1 to C6 alkyl, C1 to C3 alkyl-aryl, aryl, or -(CH2)wR11; R10 and R11 are each independently -OH, -OR12, -CO2R12, -CONHR12, or cyano; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1 to C6 alkyl-aryl; R13 is hydrogen, -OR14, or -NHCOR14; R14 is C1 to C6 alkyl, or C1 to C3 alkyl-aryl; n is 0, 1, or 2; m is 1, 2, or 3; q is 2, 3, or 4; w is 2, 3, or 4; the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently phenyl or substituted phenyl, wherein said substituted phenyl may be substituted with one to three of C1 to C4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C1 to C4 alkoxy; and a broken line represents an optional double bond, and the pharmaceutically acceptable salts thereof. These compounds are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention relates to indole derivatives, to processes and
intermediates for their preparation, to pharmaceutical compositions containing them and
to their medicinal use. The active compounds of the present invention are useful in
treating migraine and other disorders.United States Patents 4,839,377 and 4,855,314 and European Patent Application
Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The
compounds are said to be useful for the treatment of migraine.British Patent GB-A-2035310 refers to 3-aminoalkyl-1H-indole-5-thioamides
and carboxamides. The compounds are said to be useful in treating hypertension,
Raynaud's disease and migraine.European Patent Application Publication Number 303506 refers to 3-poly:hydropyridyl-5-substituted-1H-indoles.
The compounds are said to have 5HT1-receptor
agonist and vasoconstrictor activity and to be useful in treating migraine.European Patent Application Publication Number 354777 refers to N-piperidinyl:indolyl:ethyl-alkane
sulfonamide derivatives. The compounds are said to
have 5HT1-receptor agonist and vasoconstrictor activity and to be useful in treating
cephalic pain.The present invention relates to compounds of the formula
wherein Z is
R1 is equal to
A, B, D, E, and F are each independently C, N, O, or S; R2, R3, R4,
R5, and R6 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkyl-aryl,
halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, nitro, -NR7R8,
-(CH2)mOR9, -SR9, -SO2R9,-SO2NR7R8, -NR7SO2R8, -NR7CO2R9, -NR7COR9, -CONR7R8,
or-CO2R9; one of R2 and R3, R3 and R4, R4 and R5, or R5 and R6 may be taken together
to form a five-to seven-membered alkyl ring, a six-membered aryl ring, a five-to seven-membered
heteroalkyl ring having 1 heteroatom of N, O, or S, or a five- to six-membered
heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R7 and R8 are each
independently hydrogen, C1 to C6 alkyl, -(CH2)qR10, C1 to C3 alkyl-aryl, aryl, or R7 and
R8 may be taken together to form a four- to six-membered ring; R9 is hydrogen, C1 to
C6 alkyl, C1 to C3 alkyl-aryl, aryl, or -(CH2)wR11; R10 and R11 are each independently
-OH, -OR12, -CO2R12, -CONHR12, or cyano; R12 is hydrogen, C1 to C6 alkyl, aryl, or C1
to C6 alkyl-aryl; R13 is hydrogen, -OR14, or -NHCOR14; R14 is C1 to C6 alkyl or C1 to C3
alkyl-aryl; n is 0, 1, or 2; m is 1, 2, or 3; q is 2, 3, or 4; w is 2, 3, or 4; the above aryl
groups and the aryl moieties of the above alkyl-aryl groups are independently phenyl
or substituted phenyl, wherein said
</DESCRIPTION>
<CLAIMS>
A compound of the formula

wherein Z is

R
1
 is

A, B, D, E, and F are each independently C, N, O, or S; R
2
, R
3
, R
4
,
R
5
, and R
6
 are each independently hydrogen, C
1
 to C
6
 alkyl, aryl, C
1
 to C
3
 alkyl-aryl,
halogen, cyano, nitro, -NR
7
R
8
, -(CH
2
)
m
 OR
9
, -SR
9
, -SO
2
R
9
, -SO
2
NR
7
R
8
, - NR
7
SO
2
R
8
,
-NR
7
CO
2
R
9
, -NR
7
COR
9
, -CONR
7
R
8
, or -CO
2
R
9
; one of R
2
 and R
3
, R
3
 and R
4
, R
4
 and R
5
,
or R
5
 and R
6
 may be taken together to form a five- to seven-membered alkyl ring, a six-membered
aryl ring, a five- to seven-membered heteroalkyl ring having 1 heteroatom

of N, O, or S, or a five- or six-membered heteroaryl ring having 1 or 2 heteroatoms of
N, O, or S; R
7
 and R
8
 are each independently hydrogen, C
1
 to C
6
 alkyl, -(CH
2
)
q
R
10
, C
1

to C
3
 alkyl-aryl, aryl, or R
7
 and R
8
 may be taken together to form a four- to six-membered
ring; R
9
 is hydrogen, C
1
 to C
6
 alkyl, C
1
 to C
3
 alkyl-aryl, aryl: or -(CH
2
)
w
R
11
; 
R
10
 and R
11
 are each independently -OH, OR
12
, -CO
2
R
12
, -CONHR
12
, or cyano; R
12
 is
hydrogen, C
1
 to C
6
 alkyl, aryl, or C
1
 to C
6
 alkyl-aryl; R
13
 is hydrogen. -OR
14
, or
-NHCOR
14
; R
14
 is C
1
 to C
6
 alkyl or C
1
 to C
3
 alkyl-aryl; n is 0, 1, or 2; m is 1, 2, or 3; q
is 2, 3, or 4; w is 2, 3, or 4; the above aryl groups and the aryl moieties of the above

alkyl-aryl groups are independently phenyl or substituted phenyl, wherein said
substituted phenyl may be substituted with one to three of C
1
 to C
4
 alkyl, halogen,
hydroxy, cyano, carboxamido, nitro, and C
1
 to C
4
 alkoxy; and a broken line represents
an optional double bond, and the pharmaceutically acceptable salts thereof.
A compound according to claim 1 where in R
1
 is


where R
7
 and R
13
 is defined in claim 1.
A compound according to claim 2, wherein R
13
 is hydrogen.
A compound according to claim 2, wherein Z is 


where A, D, E, R
2
, R
3
, R
4
, and R
5
 are as defined in claim 1.
A compound according to claim 1 wherein R
1
 is


where R
7
 and R
13
 are as defined in Claim 1.
A compound according to claim 5, wherein R
13
 is -OR
14
 and R
14
 is -CH
3
.
A compound according to claim 5 wherein Z is


where A, D, E, R
2
, R
3
, R
4
, and R
5
 are as defined in claim 1.
A compound according to claim 1 wherein Z is


wherein R
2
 is NO
2
, CN, SO
2
CH
3
, SO
2
Ph, CONH
2
.
A compound according to claim 8 wherein R
1
 is 


wherein R
7
 and R
13
 are as defined in claim 1.
A compound according to claim 1, said compound being selected from

3-(2-dimethylaminoethyl)-5-(3,5-dinitropyrid-2-ylamino)-1H-indole;
3-(2-dimethylaminoethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
3-(2-dimethylaminoethyl)-5-(3-trifluoromethylpyrid-2-ylamino)-1H-indole;
(R)-5-(3-nitropyrid-2-ylamino)-3-(pyrrolidin-2-ylmethyl)-1H-indole;
(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(nitropyrid-2-ylamino)-1H-indole;1
(R,S)-3-(N-methylpyrrolidin-3-yl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
5-(benzoxaz-2-ylamino)-3-(2-dimethylaminoethyl)-1H-indole;
(R)-3-(N-cyclopropylmethylpyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
(R)-5-(3-nitropyrid-2-ylamino)-3-(N-(2-propynyl)pyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(3-nitropyrid-2-ylamino)-3-(N-(2-propenyl)pyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(3-nitropyrid-2-ylamino)-3-(N-propylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-3-(N-butylpyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
(R)-3-(N-ethylpyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
(R)-5-(3-nitropyrid-2-ylamino)-3-(N-pentylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-3-(N-(2-methoxyethyl)pyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
(R)-3-(N-(2-cyanoethyl)pyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-ylamino)-1H-indole;
(R)-3-(N-cyanomethyl)pyrrolidin-2-ylmethyl)-5-(3-nitropyrid-2-yl-amino)-1H-indole;
(R)-5-(3-benzylthio-1,2,4-thiadiaz-5-ylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
3-(2-dimethylaminoethyl)-5-(pyrimid-2-ylamino)-1H-indole;
3-(2-dimethylaminoethyl)-5-(3-methylsulfonylpyrid-2-ylamino)-1H-indole; 
(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(2-nitrophenylamino)-1H-indole;
(R)-5-(6-methoxy-3-nitropyrid-2-ylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(4-methyl-3-nitropyrid-2-ylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(3-nitro-5-phenylpyrid-2-ylamino)-1H-indole;
(R)-5-(3-cyanopyrid-2-ylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(6-isopropoxy-3-nitropyrid-2-ylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(4-cyano-2-nitrophenylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-(4-trifluoromethyl-2-nitrophenylamino)-1H-indole;
(R)-5-(5,6-dichloro-2-nitrophenylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
5-(4-Cyano-2-nitrophenylamino)-3-[(2R,4R)-N-methyl-4-methoxypyrrolidin-2-ylmethyl]-1H-indole;

and
(R) -5- (5-chloro-2-nitrophenylamino)-3-(N-methylpyrrolidin-2-ylmethyl)-1H
indole.
5-(3-Nitropyrid-2-ylamino)-3-(piperid-4-yl)-1H-indole.
5-(3-Nitropyrid-2-ylamino)-3-(1, 2, 5, 6-tetrahydropyrid-4-yl)-1H-indole.
5-(5-Nitropyrid-2-ylamino)-3-(1, 2, 5, 6-tetrahydropyrid-4-yl)-1H-indole.
A pharmaceutical composition for treating a condition selected from
hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster

headache, migraine, pain, and chronic paroxysmal hemicrania and headache
associated with vascular disorders comprising an amount of a compound according

to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating disorders arising from deficient
serotonergic neurotransmission comprising an amount of a compound according to

claim 1 effective in treating such a disorder and a pharmaceutically acceptable carrier. 
A process for preparing a compound of the formula 1 as defined in
claim 1 which comprises;


(a) where Z is


by reacting a compound of the formula


with a compound of the formula

 
where LG is a suitable leaving group;
(b) where Z is


by reacting a compound of the formula


with a compound of the formula

 
where LG is a suitable leaving group;
(c) where R
1
 is


by reacting a compound of the formula


with an alkylating agent of the formula R
7
-G where G is Cl, Br, I, -OSO
2
CH
3
,
-OSO
2
Ph, -OSO
2
PhCH
3
 or -OSO
2
CF
3
 and R
7
 is as defined in claim 1;
(d) where R
1
 is

 
R
7
 is -(CH
2
)
q
R
10
 and q is 2, by reacting a compound of the formula:


With an alkylating agent of the formula CH
2
=CHR
10
; and, if desired, converting
a compound of formula I to a pharmaceutically acceptable salt thereof;

wherein in the above formulae A, B, D, E, F, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
10
, R
13
, Z
and n are as defined in claim 1.
</CLAIMS>
</TEXT>
</DOC>
